首页> 外文OA文献 >In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species▿
【2h】

In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species▿

机译:伊沙康康唑(BAL4815),伏立康唑和氟康唑的体外抗真菌活性对合细菌,念珠菌,曲霉,镰刀菌和景天孢菌属的1,007种分离物▿

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Isavuconazole (BAL4815) is a promising novel broad-spectrum triazole in late-stage clinical development that has proven active in vitro against Aspergillus and Candida species. We compared the in vitro activities of this agent with those of voriconazole and fluconazole by the CLSI (formerly NCCLS) M38-A and M27-A2 procedures against a large collection of 1,007 relevant opportunistic fungi collected from 1986 to 2007: Aspergillus spp. (n = 702), Candida spp. (n = 218), Zygomycetes (n = 45), Scedosporium spp. (n = 22), and Fusarium spp. (n = 20). All Candida isolates were from patients with candidemia. For isavuconazole, these techniques were also compared with the Etest. Isavuconazole and voriconazole had MICs at which 50% and 90% of isolates were inhibited (MIC50 and MIC90), respectively, of 1 and 1 μg/ml and 0.5 and 1 μg/ml against Aspergillus spp. and of 0.015 and 0.03 μg/ml and 0.25 and 0.125 μg/ml against Candida spp. (including fluconazole-resistant strains). The MIC50 partial and complete inhibition end points of isavuconazole and voriconazole against the non-Aspergillus molds were as follows: 1 and 2 μg/ml and 16 and >16 μg/ml against Zygomycetes; 1 and 4 μg/ml and 0.25 and 0.5 μg/ml against Scedosporium apiospermum; 4 to 16 and >16 μg/ml and 4 to 8 and 16 to >16 μg/ml (ranges) against Scedosporium prolificans; and 16 and 16 μg/ml and 4 and 4 μg/ml against Fusarium spp. Isavuconazole showed minimal fungicidal concentrations for 50% and 90% of the isolates of 1 and 1 μg/ml against Aspergillus, 16 and >16 μg/ml against Candida, and 4 and >16 μg/ml against Zygomycetes, respectively, and >16 μg/ml against the remaining molds. The Etest proved to be a suitable alternative method for determining the antifungal activities of isavuconazole against Aspergillus and Candida; the Etest results showed 96% and 93% agreement with the results of the CLSI M38-A and M27-A2 methods, respectively.
机译:Isavuconazole(BAL4815)是在后期临床开发中很有前途的新型广谱三唑,已证明在体外对曲霉和念珠菌具有活性。我们通过CLSI(以前称为NCCLS)M38-A和M27-A2程序,比较了该试剂与伏立康唑和氟康唑的体外活性与针对1986年至2007年收集的1,007种相关机会性真菌:曲霉菌的体外活性。 (n = 702),念珠菌属。 (n = 218),合酵母(n = 45),Scedosporium spp。 (n = 22)和镰刀菌属。 (n = 20)。所有念珠菌分离株均来自念珠菌血症患者。对于异氟康唑,这些技术也与Etest进行了比较。 Isavuconazole和voriconazole的MIC对曲霉菌的MIC分别被抑制50%和90%(MIC50和MIC90)分别为1和1μg/ ml,0.5和1μg/ ml。和针对假丝酵母的0.015和0.03μg/ ml和0.25和0.125μg/ ml。 (包括耐氟康唑的菌株)。异伏康唑和伏立康唑对非曲霉霉菌的MIC50部分和完全抑制终点如下:针对合酵母,分别为1和2μg/ ml,以及16和> 16μg/ ml。 1、4μg/ ml和0.25和0.5μg/ ml的抗剑孢孢子;对抗多孢子孢菌的4至16和> 16μg/ ml以及4至8和16至> 16μg/ ml(范围);和针对镰刀菌属的16和16μg/ ml以及4和4μg/ ml。分别对曲霉菌1和1μg/ ml,对念珠菌为16和> 16μg/ ml,对合子菌为4和> 16μg/ ml的分离株的50%和90%的艾沙康康唑显示最小杀真菌浓度相对于其余霉菌为μg/ ml。 Etest被证明是确定伊沙康康唑对曲霉和念珠菌的抗真菌活性的合适替代方法。 Etest结果与CLSI M38-A和M27-A2方法的结果分别达到96%和93%一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号